KDM4B Histone Demethylase Inhibition Attenuates Tumorigenicity of Malignant Melanoma Cells by Overriding the p53-Mediated Tumor Suppressor Pathway.
apoptosis
cell cycle arrest
cytotoxicity
epigenetics
histone methylation
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
revised:
01
08
2024
received:
16
05
2024
accepted:
09
08
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Despite significant advances in the treatment of cutaneous melanoma (hereafter melanoma), the prognosis remains less favorable due to therapeutic resistance, which is presumably linked to epigenetic dysregulation. We hypothesized that the histone lysine demethylase KDM4B could play a pivotal role in controlling therapy-resistant melanoma. To validate our hypothesis, we retrieved RNA sequencing data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) program and observed upregulation of KDM4B in both primary and metastatic melanoma, which was associated with poor survival. To explore its role, we used murine B16, human SK-MEL-5, and G-361 melanoma cells as in vitro models of melanoma. We found that KDM4B inhibition using NCGC00244536 increased global levels of H3K9me3 and downregulated the expressions of cell cycle progression-related genes Cdk1, Cdk4, Ccnb1, and Ccnd1. Moreover, genetic ablation of KDM4B or its chemical inhibition using NCGC00244536 reduced p53 production by upregulating MDM2, which enhances the proteolytic degradation of p53. Interestingly, despite the reduction of p53, these interventions augmented apoptosis and senescence-induced cell death by activating pathways downstream of p53, as evidenced by reduced levels of pro-survival Bcl-2 and Bcl-xL proteins and increased production of pro-apoptotic cleaved caspase-3, caspase-7, Bax, and the senescence inducer Cdkn1a. Compared to the FDA-approved anti-melanoma agent dacarbazine, NCGC00244536 exhibited more pronounced cytotoxic and antiproliferative effects in melanoma cells. Importantly, NCGC00244536 demonstrated minimal cytotoxicity to low Kdm4b-expressing mouse embryonic fibroblasts. In conclusion, our findings suggest that KDM4B inhibition can override the antitumor effect of p53, and potentially serve as a therapeutic strategy for melanoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30643Subventions
Organisme : This work was funded in part through the Grantsin-Aid for Scientific Research (KAKENHI) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (grant number 21K08261 [AUH]).
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
J. J. Luke, K. T. Flaherty, A. Ribas, and G. V. Long, “Targeted Agents and Immunotherapies: Optimizing Outcomes in Melanoma,” Nature Reviews Clinical Oncology 14, no. 8 (2017): 463–482.
I. Kozar, C. Margue, S. Rothengatter, C. Haan, and S. Kreis, “Many Ways to Resistance: How Melanoma Cells Evade Targeted Therapies,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1871, no. 2 (2019): 313–322.
J. Berk‐Krauss, J. A. Stein, J. Weber, D. Polsky, and A. C. Geller, “New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016,” American Journal of Public Health 110, no. 5 (2020): 731–733.
M. Arnold, D. Singh, M. Laversanne, et al., “Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040,” JAMA Dermatology 158, no. 5 (2022): 495–503.
M. Khaliq, M. Manikkam, E. D. Martinez, and M. Fallahi‐Sichani, “Epigenetic Modulation Reveals Differentiation State Specificity of Oncogene Addiction,” Nature communications 12, no. 1 (2021): 1536.
G. K. Griffin, J. Wu, A. Iracheta‐Vellve, et al., “Epigenetic Silencing by SETDB1 Suppresses Tumour Intrinsic Immunogenicity,” Nature 595, no. 7866 (2021): 309–314.
T. Strub, R. Ballotti, and C. Bertolotto, “The ‘ART’ of Epigenetics in Melanoma: From Histone ‘Alterations, to Resistance and Therapies’,” Theranostics 10, no. 4 (2020): 1777–1797.
J. Sterling, S. V. Menezes, R. H. Abbassi, and L. Munoz, “Histone Lysine Demethylases and Their Functions in Cancer,” International Journal of Cancer 148, no. 10 (2021): 2375–2388.
J. B. Loureiro, M. Abrantes, P. A. Oliveira, and L. Saraiva, “P53 in Skin Cancer: From a Master Player to a Privileged Target for Prevention and Therapy,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1874, no. 2 (2020): 188438.
V. O. Melnikova, S. V. Bolshakov, C. Walker, and H. N. Ananthaswamy, “Genomic Alterations in Spontaneous and Carcinogen‐Induced Murine Melanoma Cell Lines,” Oncogene 23, no. 13 (2004): 2347–2356.
J. B. Loureiro, L. Raimundo, J. Calheiros, et al., “Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance,” Cancers 13, no. 7 (2021): 1648.
D. Perna, F. A. Karreth, A. G. Rust, et al., “BRAF Inhibitor Resistance Mediated by the AKT Pathway in an Oncogenic BRAF Mouse Melanoma Model,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 6 (2015): E536–E545.
B. Plitzko, E. N. Kaweesa, and S. Loesgen, “The Natural Product Mensacarcin Induces Mitochondrial Toxicity and Apoptosis in Melanoma Cells,” Journal of Biological Chemistry 292, no. 51 (2017): 21102–21116.
D. M. Lee, I. Y. Kim, M. J. Seo, M. R. Kwon, and K. S. Choi, “Nutlin‐3 Enhances the Bortezomib Sensitivity of p53‐defective Cancer Cells by Inducing Paraptosis,” Experimental & Molecular Medicine 49, no. 8 (2017): 365.
D. S. Chandrashekar, S. K. Karthikeyan, P. K. Korla, et al., “UALCAN: An Update to the Integrated Cancer Data Analysis Platform,” Neoplasia 25 (2022): 18–27.
B. Badal, A. Solovyov, S. Di Cecilia, et al., “Transcriptional Dissection of Melanoma Identifies a High‐Risk Subtype Underlying TP53 Family Genes and Epigenome Deregulation,” JCI Insight 2, no. 9 (2017): e92102, https://doi.org/10.1172/jci.insight.92102.
L. Duan, G. Rai, C. Roggero, et al., “KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB‐Regulated Genes,” Chemistry & Biology 22, no. 9 (2015): 1185–1196.
M. Chanda and M. S. Cohen, “Advances in the Discovery and Development of Melanoma Drug Therapies,” Expert Opinion on Drug Discovery 16, no. 11 (2021): 1319–1347.
Z. Ji, R. Kumar, M. Taylor, et al., “Vemurafenib Synergizes With nutlin‐3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth,” Clinical Cancer Research 19, no. 16 (2013): 4383–4391.
A. U. Hasan, M. Obara, S. Sato, Y. Kondo, and E. Taira, “CD146/MCAM Links Doxorubicin‐Induced Epigenetic Dysregulation to the Impaired Fatty Acid Transportation in H9c2 Cardiomyoblasts,” Biochemical and Biophysical Research Communications 693 (2024): 149370.
A. U. Hasan, K. Ohmori, T. Hashimoto, et al., “GPR120 in Adipocytes has Differential Roles in the Production of Pro‐Inflammatory Adipocytokines,” Biochemical and Biophysical Research Communications 486, no. 1 (2017): 76–82, https://doi.org/10.1016/j.bbrc.2017.03.001.
A. U. Hasan, K. Ohmori, T. Hashimoto, et al., “Pioglitazone Promotes Preadipocyte Proliferation by Downregulating p16Ink4a,” Biochemical and Biophysical Research Communications 411, no. 2 (2011): 375–380.
A. U. Hasan, K. Ohmori, T. Hashimoto, et al., “Increase in Tumor Suppressor Arf Compensates Gene Dysregulation in In Vitro Aged Adipocytes,” Biogerontology 18, no. 1 (2017): 55–68, https://doi.org/10.1007/s10522-016-9661-9.
Z. Wang, H. Cai, E. Zhao, and H. Cui, “The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression,” Frontiers in Cell and Developmental Biology 9 (2022): 790129.
S. Erdmann, D. Seidel, H. G. Jahnke, M. Eichler, J. C. Simon, and A. A. Robitzki, “Induced Cross‐Resistance of BRAFV600E Melanoma Cells to Standard Chemotherapeutic Dacarbazine After Chronic PLX4032 Treatment,” Scientific Reports 9, no. 1 (2019): 30.
S. Zhu, Y. Li, L. Zhao, et al., “TSA‐Induced JMJD2B Downregulation Is Associated With Cyclin B1‐Dependent Survivin Degradation and Apoptosis in LNCap Cells,” Journal of Cellular Biochemistry 113, no. 7 (2012): 2375–2382.
J. Yang, S. Milasta, D. Hu, et al., “Targeting Histone Demethylases in MYC‐Driven Neuroblastomas With Ciclopirox,” Cancer Research 77, no. 17 (2017): 4626–4638.
W. W. Deng, Q. Hu, Z. R. Liu, et al., “KDM4B Promotes DNA Damage Response via STAT3 Signaling and Is a Target of CREB in Colorectal Cancer Cells,” Molecular and Cellular Biochemistry 449, no. 1–2 (2018): 81–90.
Y. Yu, K. Schleich, B. Yue, et al., “Targeting the Senescence‐Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma,” Cancer Cell 33, no. 2 (2018): 322–336.e8.
J. Li, Y. Wang, Y. Luo, et al., “USP5‐Beclin 1 Axis Overrides p53‐Dependent Senescence and Drives Kras‐Induced Tumorigenicity,” Nature Communications 13, no. 1 (2022): 7799.